Randomized trials with patient-reported outcomes are commonly plagued by missing data. The analysis of such trials relies on untestable assumptions about the missing data mechanism. To address this issue, it has been recommended that the sensitivity of the trial results to assumptions should be a mandatory reporting requirement. In this paper, we discuss a recently developed methodology (Scharfstein et al., Biometrics, 2018) for conducting sensitivity analysis of randomized trials in which outcomes are scheduled to be measured at fixed points in time after randomization and some subjects prematurely withdraw from study participation. The methodology is explicated in the context of a placebo-controlled randomized trial designed to evaluate a treatment for bipolar disorder. We present a comprehensive data analysis and a simulation study to evaluate the performance of the method. A software package entitled SAMON (R and SAS versions) that implements our methods is available at www.missingdatamatters.org.
Introduction
Missing outcome data are a widespread problem in clinical trials, including those with patient-reported outcomes. Since such outcomes require active engagement of patients, and patients, while encouraged, are not required to remain or provide data while on-study, high rates of missing data can be expected.
To understand the magnitude of this issue, we reviewed all randomized trials a reporting five major patientreported outcomes (SF-36, SF-12, Patient Health Questionnaire-9, Kansas City Cardiomyopathy Questionnaire, Minnesota Living with Heart Failure Questionnaire) published in five leading general medical journals (New England Journal of Medicine, Journal of the American Medical Association, Lancet, British Medical Journal, PLoS One) between 1 January 2008 and 31 January 2017. We identified 145 studies, which are summarized in the online supplement. There is large variation in the percentages of missing data, with 78.6% of studies reporting percentages greater than 10%, 43.4% greater than 20% and 24.8% greater than 30%. Fielding et al. 1 conducted a similar review of clinical trials reporting quality of life outcomes in four of these journals during 2005/2006 and found a comparable distribution of missing data percentages. Given the quality of these journals, it is likely that the percentages reported in Fielding et al. 1 and in the online supplement are an optimistic representation of percentages of missing data across the universe of clinical trials with patient-reported outcomes published in the medical literature.
Missing outcome data complicate the inferences that can be drawn about treatment effects. While unbiased estimates of treatment effects can be obtained from trials with no missing data, this is no longer true when data are missing on some patients. The essential problem is that inference about treatment effects relies on unverifiable assumptions about the nature of the mechanism that generates the missing data. While we may know the reasons for missing data, we do not know the distribution of outcomes for patients with missing data, how it compares to that of patients with observed data and whether differences in these distributions can be explained by the observed data.
It is widely recognized that the way to address the problem caused by missing outcome data is to posit varying assumptions about the missing data mechanism and evaluate how inference about treatment effects is affected by these assumptions. Such an approach is called ''sensitivity analysis.'' A 2010 National Research Council (NRC) report entitled ''The Prevention and Treatment of Missing Data in Clinical Trials'' 2 and a follow-up manuscript published in the New England Journal of Medicine 3 recommends: ''Sensitivity analyses should be part of the primary reporting of findings from clinical trials. Examining sensitivity to the assumptions about the missing data mechanism should be a mandatory component of reporting.'' Li et al. 4 echoed this recommendation (see Standard 8) The set of possible assumptions about the missing data mechanism is very large and cannot be fully explored. As discussed in Scharfstein et al., 5 there are three main approaches to sensitivity analysis: ad-hoc, local and global.
. Ad hoc sensitivity analysis involves analyzing data using a few different analytic methods (e.g. last or baseline observation carried forward, complete or available case analysis, mixed models, imputation) and evaluating whether the resulting inferences are consistent. The problem with this approach is that consistency of inferences across the various methods does not imply that there are no reasonable assumptions under which the inference about the treatment effect is different. . Local sensitivity analysis [6] [7] [8] [9] [10] evaluates whether inferences are robust in a small neighborhood around a reasonable benchmark assumption, such as the classic missing at random assumption. 11 Unfortunately, this approach does not address whether the inferences are robust to plausible assumptions outside of the local neighborhood.
. Global sensitivity analysis 5, [12] [13] [14] [15] [16] [17] emphasized in Chapter 5 of the NRC report, 2 evaluates robustness of results across a much broader range of assumptions that include a reasonable benchmark assumption and a collection of additional assumptions that trend toward best and worst case assumptions. From this analysis, it can be determined how much deviation from the benchmark assumption is required in order for the inferences to change. If the deviation is judged to be sufficiently far from the benchmark assumption, then greater credibility is lent to the benchmark analysis; if not, the benchmark analysis can be considered to be fragile. Some researchers have dubbed this approach ''tipping point analysis.'' 18, 19 In this paper, we consider randomized clinical trials in which patient-reported outcomes are scheduled to be measured at baseline (prior to randomization) and at a fixed number of post-baseline assessment times. We assume that some patients discontinue participation prior to the final assessment time and that all outcomes are observed while the patients are on-study. This assumption implies that there is no intermittent missing outcome data. We discuss a recently developed methodology 16 for conducting global sensitivity analysis of such trials. We explicate the methodology in the context of a randomized trial designed to evaluate the efficacy of quetiapine fumarate for the treatment of patients with bipolar disorder.
Quetiapine bipolar trial
The Quetiapine bipolar trial was a multi-center, placebo-controlled, double-dummy study in which patients with bipolar disorder were randomized equally to one of three treatment arms: placebo, Quetiapine 300 mg/day or Quetiapine 600 mg/day. 20 Randomization was stratified by type of bipolar disorder: 1 or 2. A key secondary patient-reported endpoint was the short-form version of the Quality of Life Enjoyment Satisfaction Questionnaire (QLESSF 21 ), which was scheduled to be measured at baseline, week 4, and week 8. b We focus on the subset of 234 patients with bipolar 1 disorder who were randomized to either the placebo (n ¼ 116) or 600 mg/day (n ¼ 118) arms. The 600 mg/day dose was titrated to achieve the target by Day 8. In each treatment group, a dose reduction of 100 mg was allowed to improve tolerability. At the discretion of the investigator, patients could be discontinued from study treatment and assessments at any time for reasons including withdrawal of informed consent, worsening psychiatric symptoms, use of prohibited psychotropic medications, pregnancy, occurrence of a clinically significant serious adverse event, and significant irregularities in compliance with study medication. Patients were free to discontinue their participation in the study at any time. Those who discontinued were asked about the reasons for their discontinuation and about the presence of any adverse events. The use of psychoactive drugs, with the exception of lorazepam and zolpidem tartrate during the first three weeks, was prohibited. Investigators were allowed to prescribe other medications for the safety and well-being of the participant.
In the placebo arm, 14 (12.1%), 16 (13.8%), and 21 (18.1%) patients dropped out due to adverse events, lack of efficacy, and other reasons (primarily loss to follow-up, withdrawal consent and protocol non-compliance), respectively. In the 600 mg/day arm, 28 (23.7%) and 22 (18.6%) patients dropped out due to adverse events and other reasons (primarily loss to follow-up), respectively; no patients dropped out due to lack of efficacy. Only 65 patients (56%) in the placebo arm and 68 patients (58%) in the 600 mg/day arm had a complete set of QLESSF scores. Figure 1 displays the treatment-specific trajectories of mean QLESSF scores, stratified by last available measurement. Note that patients with complete data tend to have higher average QLESSF scores, suggesting that a complete-case analysis could be biased. Figure 2 displays, by treatment group, the last observed QLESSF scores, stratified by last visit on-study and reason for drop-out (for premature withdrawals). The distribution of last QLESSF scores for premature withdrawals, regardless of reason, has sizable overlap with the distribution of QLESSF scores of completers.
We seek to compare the mean QLESSF outcomes at week 8 between the two treatment groups in a hypothetical world in which outcomes are collected on all individuals, regardless of time on-study. The validity of assumptions will depend on what is imagined about treatments that patients receive off-study. Given ethical considerations, we are not imagining the continuation of assigned treatment plan after the occurrence of intolerable side effects or lack of efficacy. Rather, we imagine that patients receive treatment as close to the assigned treatment plan as ethically possible. This includes dose modifications to counter side effects that are considered dose related (e.g. somnolence), use of lorazepam or zolpidem tartrate after three weeks to treat anxiety or insomnia, and, if necessary, use of psychoactive active medications to address escalating depression or suicidal ideation. The difference of the treatment-specific mean QLESSF outcomes at week 8 under this imaginary, yet plausible, treatment scenario is the target estimand of interest.
The sensitivity analysis methodology developed in this paper does not explicitly incorporate reason for premature withdrawal.
Global sensitivity analysis
Chapter 5 of the NRC report 2 lays out a general framework for global sensitivity analysis. In this framework, inference about treatment effects requires two types of assumptions: (i) untestable assumptions about the distribution of outcomes among those with missing data and (ii) testable assumptions that serve to increase the efficiency of estimation. Type (i) assumptions are required to ''identify'' parameters of interest: identification means that one can mathematically express parameters of interest (e.g. treatment arm-specific means, treatment effects) in terms of the distribution of the observed data. In other words, if one were given the distribution of the observed data and given a type (i) assumption, then one could compute the value of the parameter of interest. In the absence of identification, one cannot learn the value of the parameter of interest based only on knowledge of the distribution of the observed data. Identification implies that the parameters of interest can, in theory, be estimated if the sample size is large enough.
There are an infinite number of ways of positing type (i) assumptions. It is impossible to consider all such assumptions. A common way of positing these assumptions is to (a) stratify individuals with missing outcomes according to the data that were able to be collected on them and the occasions at which the data were collected, and (b) separately for each stratum, hypothesize a connection (or link) between the distribution of the missing outcomes with the distribution of these outcomes for patients who share the same recorded data and for whom the distribution is identified.
The connection that is posited in (b) is a type (i) assumption. The problem with this approach is that the stratum of people who share the same recorded data will typically be very small (e.g. the number of patients who share exactly the same baseline data will be very small). As a result, it is necessary to draw strength across strata by ''smoothing.'' Smoothing is required because, in practice, we are not working with large enough sample sizes. Without smoothing, the data analysis will not be informative because the uncertainty (i.e. standard errors) of the parameters of interest will be too large to be of substantive use. Thus, it is necessary to impose type (ii) smoothing assumptions. Type (ii) assumptions are testable (i.e. place restrictions on the distribution of the observed data) and should be scrutinized via model checking.
The global sensitivity framework proceeds by parameterizing (i.e. indexing) the connections (i.e. type (i) assumptions) in (b) above via sensitivity analysis parameters. The parameterization is configured so that a specific value of the sensitivity analysis parameters (typically set to zero) corresponds to a benchmark connection that is considered reasonably plausible and sensitivity analysis parameters further from the benchmark value represent more extreme departures from the benchmark connection.
The global sensitivity analysis strategy that we propose is focused on separate inferences for each treatment arm, which are then combined to evaluate treatment effects. Until the last part of this section, our focus will be on estimation of the mean outcome at week 8 (in a world without missing outcomes) for one of the treatment groups and we will suppress reference to treatment assignment.
Notation and data structure
Let Y 0 , Y 1 and Y 2 denote the QLESSF scores scheduled to be collected at baseline, week 4 and week 8, respectively. Let R k be the indicator that Y k is observed. We assume R 0 ¼ 1 and that R k ¼ 0 implies R kþ1 ¼ 0 (i.e. missingness is monotone). We refer to a patient as on-study at visit
Þ, which is drawn from some distribution P Ã contained within a set of distributions M (to be discussed later). Throughout, the superscript Ã will be used to denote the true value of the quantity to which it is appended. Any distribution P 2 M can be represented in terms of the following distributions:
We assume that n independent and identically distributed copies of O are observed. The goal is to use these data to draw inference about
When necessary, we will use the subscript i to denote data for individual i.
Benchmark assumption (missing at random)
Missing at random 11 is a widely used assumption for analyzing longitudinal studies with missing outcome data. To understand this assumption, we define the following strata:
. Mathematically, we can express these assumptions as follows:
and
Using Bayes' rule, we can re-write these expressions as
Written in this way, missing at random implies that the drop-out process is stochastic with the following properties:
. The decision to discontinue the study before visit 1 is like the flip of a coin with probability depending on the value of the outcome at visit 0, . For those on-study at visit 1, the decision to discontinue the study before visit 2 is like the flip of a coin with probability depending on the value of the outcomes at visits 1 and 0.
Under missing at random, Ã is identified. That is, it can be expressed as a function of the distribution of the observed data. Specifically
Before proceeding to the issue of estimation, we will build a class of assumptions around the missing at random assumption using a modeling device called exponential tilting. 22 
Missing not at random and exponential tilting
To build a class of missing not at random assumptions, consider equation (1) of the missing at random assumption. This equation is equivalent to the following two assumptions
where . For all y 0 and y 1 , the distribution of Y 2 for patients in strata A 0 ð y 1 , y 0 Þ is the same as the distribution of Y 2 for patients in strata B 1 ð y 1 , y 0 Þ It has been referred to as the ''non-future'' dependence assumption 23 because it implies that R 1 (i.e. the decision to drop-out before visit 1) is independent of Y 2 (i.e. the future outcome) after conditioning on the Y 0 (i.e. the past outcome) and Y 1 (i.e. the most recent outcome). We will retain this assumption.
Next, we impose the following exponential tilting ''linking'' assumptions:
where r k ðY k ; k Þ is a specified function Y k and sensitivity analysis parameter k for k ¼ 1, 2. To simplify the sensitivity analysis, we further assume
where rðÁÞ is a specified increasing function of its argument and is a common (across time) sensitivity analysis parameter. The missing not at random class of assumptions that we propose involve equations (6), (8) to (10) , where rðÁÞ is considered fixed and is a sensitivity analysis parameter that serves as the class index. Importantly, notice how equation (8) reduces to equation (7) and equation (9) reduces to equation (2) when ¼ 0. Thus, when ¼ 0, the MAR assumption is obtained. When 4 0 (<0), note that equations (8) and (9) imply . For all y 0 , the distribution of Y 1 for patients in strata A 0 ð y 0 Þ is weighted more heavily (i.e. tilted) to higher (lower) values than the distribution of Y 1 for patients in strata B 1 ð y 0 Þ, . For all y 0 , y 1 , the distribution of Y 2 for patients in strata A 1 ð y 1 , y 0 Þ is weighted more heavily weighted (i.e. tilted) to higher (lower) values than the distribution of Y 2 for patients in strata B 2 ð y 1 , y 0 Þ.
The amount of ''tilting'' increases with the magnitude of . Using Bayes' rule, we can re-write expressions (6), (8) to (10) succinctly as
Written in this way, the drop-out process is stochastic with the following properties:
. The decision to discontinue the study before visit 1 is like the flip of a coin with probability depending on the value of the outcome at visit 0 and, in a specified way, the value of the outcome at visit 1. . For those on-study at visit 1, the decision to discontinue the study before visit 2 is like the flip of a coin with probability depending on the value of the outcomes at visits 1 and 0 and, in a specified way, the value of the outcome at visit 2.
For given , Ã is identified. Specifically,
where
Inference
For given , formula (13) shows that (13) . How can we estimate these latter quantities? With the exception of F Ã 0 ð y 0 Þ, it is tempting to think that we can use non-parametric procedures to estimate these quantities. For example, a nonparametric estimate of F Ã 2 ð y 2 j y 1 , y 0 Þ would take the form
This estimator will perform very poorly (i.e. have high levels of uncertainly in moderate sample sizes) because the number of subjects who complete the study (i.e. R 2 ¼ 1) and are observed to have outcomes at visits 1 and 0 exactly equal to y 1 and y 0 will be very small and can only be expected to grow very slowly as the sample size increases. As a result, a plug-in estimator of Ã that uses such non-parametric estimators will perform poorly. We address this problem in three ways.
Testable assumptions
First, we make the estimation task slightly easier by assuming that
That is, equation (14) states that, among subjects who complete the study, information about Y 0 does not provide any information about the distribution of Y 2 above and beyond information about Y 1 and equation (15) states that, among subjects on-study at visit 1, information about Y 0 does not influence of the risk of dropping out before visit 2 above and beyond information about Y 1 . These assumptions are, with large enough samples, testable from the observed data. As such, we distinguish them from type (i) assumptions and refer to them as type (ii) assumptions.
Kernel smoothing with cross-validation
Second, we estimate F 
This estimator allows all completers to contribute, not just those with Y 1 values equal to y 1 ; it assigns weight to completers according to how far their Y 1 values are from y 1 , with closer values assigned more weight. The larger F 2 , the larger the influence of values of Y 1 further from y 1 on the estimator. As F 2 ! 1, the contribution of each completer to the estimator becomes equal, yielding bias but low variance. As F 2 ! 0, only completers with Y 1 values equal to y 1 contribute, yielding low bias but high variance.
To address the bias-variance trade-off, cross-validation 24 is typically used to select F 2 . In cross-validation, the dataset is randomly divided into J (typically, 10) approximately equal parts. Each part is called a validation set. Let V j be the indices of the subjects in the jth validation set. Let n j be the associated number of subjects. Let F ð j Þ 2 ð y 2 j y 1 ; F 2 Þ be the estimator of F Ã 2 ð y 2 j y 1 Þ based on the dataset that excludes the jth validation set (referred to as the jth training set). If F 2 is a good choice, then one would expect
will be small, whereF 2 ð y 2 Þ is the empirical distribution of Y 2 among subjects on-study at visit 2. In equation (16) , the quantity in the vertical braces is a measure of how well the estimator of F 2 ð y 2 j y 1 Þ based on the jth training set ''performs'' on the jth validation set. For each individual i in the jth validation set with an observed outcome at visit 2, we measure, by the quantity above the horizontal brace in equation (16) 
where F 1 is the minimizer of
; andF 1 ð y 1 Þ is the empirical distribution of Y 1 among subjects on-study at visit 1. Further, we estimate H
where H k is the minimizer of
andĤ k is the proportion of individual with drop-out between visits k À 1 and k among those on-study at visit k-1.
Correction procedure
The cross-validation procedure for selecting tuning parameters achieves optimal finite-sample bias-variance tradeoff for the quantities requiring smoothing, i.e. the conditional distribution functions F Ã k ð y k j y kÀ1 Þ and probability mass functions H Ã k ð y kÀ1 Þ. This optimal trade-off is usually not optimal for estimating Ã . In fact, the plug-in estimator of Ã could possibly suffer from excessive and asymptotically non-negligible bias due to inadequate tuning. This may prevent the plug-in estimator from enjoying regular asymptotic behavior, upon which statistical inference is generally based. In particular, the resulting estimator may have a slow rate of convergence, and common methods for constructing confidence intervals, such as the Wald and bootstrap intervals, can have poor coverage properties. Thus, our third move is to ''correct'' the plug-in estimator. Specifically, the goal is to construct an estimator that is ''asymptotically linear'' (i.e. can be expressed as the average of i.i.d. random variables plus a remainder term that is asymptotically negligible).
We now motivate the correction procedure. Let M be the class of distributions for the observed data O that satisfy constraints (14) and (15) . It can be shown that, for P 2 M
where P ðO; Þ is a ''derivative'' of ðÁ; Þ at P and RemðP, P Ã ; Þ is a ''second-order'' remainder term which converges to zero as P tends to P Ã . This derivative is used to quantify the change in ðP; Þ resulting from small perturbations in P; it also has mean zero (i.e. E Ã ½ P Ã ðO; Þ ¼ 0). The remainder term is second order in the sense that it can be written as or bounded by the product of terms involving differences between (functionals of) P and P Ã .
Equation (17) plus some simple algebraic manipulation teaches us that
whereP is the estimated distribution of P Ã discussed in the previous section. Under smoothness and boundedness conditions, term (19) will be o P Ã ðn À1=2 Þ (i.e. will converge in probability to zero even when it is multiplied by ffiffi ffi n p ). ProvidedP converges to P Ã at a reasonably fast rate, term (20) will also be o P Ã ðn À1=2 Þ. The second term in equation (18) prevents us from concluding that the plug-in estimator can be essentially represented as an average of i.i.d terms plus o P Ã ðn À1=2 Þ terms. However, by adding the second term in equation (18) to the plug-in estimator, we can construct a ''corrected'' estimator that does have this representation. Formally, the corrected estimator is
The practical implication is that converges in probability to Ã and
With this representation, we see that P Ã ðO; Þ is the so-called influence function. The efficient influence function in model M is presented in Appendix 1.
Confidence interval construction
For given , there are many ways to construct confidence intervals for Ã . Above, we discussed the Wald-based technique. In Section 6, we present the results of a simulation study in which this technique results in poor coverage in moderately sized samples. The poor coverage can be explained in part due to the fact thatðÞ 2 can be severely downward biased in finite samples. 25 Resampling-based procedures may be used to improve performance. A first idea is to consider the jackknife estimator for . This estimator is known to be conservative, 26 but is the ''method of choice if one does not want to do bootstrap computations.'' 25 Using the jackknife estimator of the variance, one can construct a Wald confidence interval with replaced by JK, . Our simulation study in Section 6 demonstrates that these latter intervals perform better, but still have coverage lower than desired.
Another idea is to use studentized-t bootstrap. Here, confidence intervals are formed by choosing cutpoints based on the distribution of ). An equal-tailed confidence interval takes the form
where t q is the qth quantile of equation (21) . A symmetric confidence interval takes the form
where t Ã 1À is selected so that ð1 À Þ of the distribution of equation (21) is between Àt Ã 1À and t Ã 1À . Our simulation study in Section 6 shows that the symmetric studentized-t bootstrap with jackknife standard errors performs best. We used this procedure in our data analysis.
Bootstrap
In terms of bootstrapping, there are two main choices: non-parametric and parametric. The advantage of nonparametric bootstrap is that it does not require a model for the distribution of the observed data. Since our analysis depends on correct specification and on estimation of such a model, it makes sense to use this model to bootstrap observed datasets. In our data analysis and simulation study, we use the estimated distribution of the observed data to generate bootstrapped observed datasets. Specifically, we generated treatment-specific datasets by drawing data for each of n individuals as follows:
Analysis of quetiapine trial
The first step of the analysis is to estimate the smoothing parameters and assess the goodness of fit of our models for H Ã j (drop-out) and F Ã j (outcome). We assumed a common smoothing parameter for the H Ã j (j ¼ 1, 2) models and a common smoothing parameter for the F Ã j (j ¼ 1, 2) models; F Ã 0 was estimated by its empirical distribution. The estimated smoothing parameters for the drop-out (outcome) model are 11.54 (6.34) and 9.82 (8.05) for the placebo and 600 mg/day Quetiapine arms, respectively. In the placebo arm, the observed percentages of last being seen at visits 0 and 1 among those at risk at these visits are 8.62% and 38.68%, respectively. Estimates derived from the estimated model for the distribution of the observed data are 7.99% and 38.19%, respectively. For the 600 mg/day Quetiapine arm, the observed percentages are 11.02% and 35.24% and the model-based estimates are 11.70% and 35.08%. In the placebo arm, the Kolmogorov-Smirnov distances between the empirical distribution of the observed outcomes and the model-based estimates of the distribution of outcomes among those on-study at visits 1 and 2 are 0.013 and 0.033, respectively. In the 600 mg/day Quetiapine arm, these distances are 0.013 and 0.022. These results suggest that our model for the observed data fits the observed data well.
Under missing at random, the estimated values of Ã are 46.45 (95% CI: 42.35, 50.54) and 62.87 (95% CI: 58.60, 67.14) for the placebo and 600 mg/day Quetiapine arms, respectively. The estimated difference between 600 mg/day Quetiapine and placebo is 16.42 (95% 10.34, 22.51), which represents both a statistically and clinically significant improvement in quality of life in favor of 600 mg/day Quetiapine. In our sensitivity analysis, we set r(y) ¼ y and ranged the sensitivity analysis parameter from À10 to 10 in each treatment arm.
e Figure 3 presents treatment-specific estimates (along with 95% pointwise confidence intervals) of Ã as a function of . Figure 4 displays a contour plot of the estimated differences between mean QLESSF at visit 2 for 600 mg/day Quetiapine vs. placebo for various treatment-specific combinations of the sensitivity analysis parameters. The point (0, 0) corresponds to the MAR assumption in both treatment arms. The figure shows that the differences are statistically significant (represented by dots) in favor of 600 mg/day Quetiapine at almost all combinations of the sensitivity analysis parameters. Only when the sensitivity analysis parameters are highly differential (e.g. ðplaceboÞ ¼ 8 and ðQuetiapineÞ ¼ À8) are the differences no longer statistically significant.
To help interpret the treatment-specific sensitivity analysis parameters, see Figures 5 and 6. Figure 5 displays treatment-specific differences between the estimated mean QLESSF at visit 2 among non-completers and the estimated mean among completers, as a function of . For example, when ¼ À10, non-completers are estimated to have more than 20 points lower quality of life than completers; this holds for both treatment arms. In contrast, when ¼ 10, non-completers are estimated to have 6 and 11 points higher quality of life than completers in the placebo and 600 mg/day Quetiapine arms, respectively. The plausibility of can be judged with respect the plausibility of these differences. In this setting, it may be considered unreasonable that, in aggregate, completers are worse off in terms of quality of life than non-completers, in which case should be restricted to be less than 6 in the placebo arm and less than 3 in the 600 mg/day Quetiapine arm. Figure 6 displays the estimated treatment-specific (placebo -first row, 600 mg/day Quetiapine -second row) conditional mean of Y k given R k ¼ 0, R kÀ1 ¼ 1 and Y kÀ1 ¼ y kÀ1 (k ¼ 1 left column, k ¼ 2 right column) for various choices of . The figure also displays the last QLESSF scores (with symbol for reason) for those patients who dropped out prematurely. For each of these patients, we can see, as a function of , the predicted mean outcome at the next visit after dropout. For almost all , the figures show that when the last measured QLESSF score is low (high) the predicted mean at the next visit tends to higher (lower). It makes sense that those who leave the study with low quality of life scores may start to receive care, prohibited by the original trial protocol, that lead to an improvement in outcomes. In addition, ''regression to the mean'' can play a role for patients with low and high quality of life scores. In both groups, the curves for À5 1 appear more plausible than those for more extreme values of . Note that the plausible set includes the benchmark missing at random assumption. Applying this range to Figure 4 , we can see that the conclusions under MAR are robust.
Simulation study
To evaluate the statistical properties of our proposed procedure, we conducted a realistic simulation study that mimics the data structure in the Quetiapine study. Using the algorithm described in Section 4.5, we generated 2500 placebo and Quetiapine datasets using the estimated distributions of the observed data from the Quetiapine study as the true data generating mechanisms. For given treatment-specific , these true data generating mechanisms can be mapped, using equation (13) , to a true value of Ã . For each dataset, the sample size was to set to 116 and 118 in the placebo and 600 mg/day Quetiapine arms, respectively. Table 1 reports bias and mean-squared error for the plug-in and corrected estimators, as a function of . The bias tends to be low for both estimators and the mean-squared error is lower for the corrected estimators, except at extreme values of . Table 2 reports the coverage properties of six difference methods for constructing confidence intervals: (1) Wald with influence function standard errors (Wald-IF), (2) Wald with jackknife standard errors (Wald-JK), (3) equaltailed studentized parametric bootstrap with influence function standard errors (Bootstrap-IF-ET), (4) equal-tailed studentized parametric bootstrap with jackknife standard errors (Bootstrap-JK-ET), (5) symmetric studentized parametric bootstrap with influence function standard errors (Bootstrap-IF-S), and (6) symmetric studentized parametric bootstrap with jackknife standard errors (Bootstrap-JK-S); 2000 parametric bootstraps were used. The results demonstrate that using jackknife standard errors is superior to influence function standard errors. In this simulation, the best performing procedures are Wald with jackknife standard errors and symmetric studentized parametric bootstrap with jackknife standard errors, with the latter experiencing, for some values of , coverages 1-2% higher than nominal levels. In other simulations (reported elsewhere), we have found that Wald with jackknife standard errors can have lower than nominal levels of coverage. Thus, we recommend using symmetric studentized parametric bootstrap with jackknife standard errors. 
Discussion
Our review of leading medical journals demonstrated that missing data are a common occurrence in randomized trials with patient-reported outcomes. As per the 2010 NRC report, 2 it is essential to evaluate the robustness of trial results to untestable assumptions about the underlying missing data mechanism. In this paper, we have presented a methodology 16 for conducting global (as opposed to ad-hoc or local) sensitivity analysis of trials in which (1) outcomes are scheduled to be measured at fixed points after randomization and (2) missing data are monotone. While we developed our method in the context of a motivating example with two post-baseline measurements, it naturally generalizes to studies with more measurements. 16 Our sensitivity analysis is anchored around the commonly used missing at random assumption. If the consumer of the analysis does not trust the MAR assumption in one or both of the treatment arms, s/he can easily evaluate inferences under alternative choices of the sensitivity analysis parameters. We have developed a software package called SAMON to implement our procedure. R and SAS versions of the software are available at www. missingdatamatters.org.
From a labeling perspective, a disadvantage of our sensitivity analysis procedure is that it does not produce an answer in the traditional sense, i.e. point estimate, confidence interval, p-value. One way to address this issue is to synthesize the results of the sensitivity analysis using the ignorance/uncertainty regions approach of Vansteelandt et al. 27 We have found that our procedure can be sensitive to outliers. In fact, we discarded two patients (one from each treatment arm) from the Quetiapine study because of their undue influence. In the placebo arm, the patient was a completer and had baseline, visit 1 and visit 2 raw scores of 17, 26 and 48, respectively. At ¼ 10, the scaled absolute DFBETA for this observation was 2.75 with the next largest absolute DFBETA being 1.13. In the Quetiapine arm, the patient was a completer and had baseline, visit 1 and visit 2 raw scores of 31, 29 and 18, respectively. At ¼ À10, the scaled absolute DFBETA for this observation was 3.20 with the next largest absolute DFBETA being 0.52. One way to address the issue of outliers would be the robustify the influence function using ideas from the robust statistics literature. 28 Our methodology does not currently handle (a) reasons for premature withdrawal, (b) auxiliary covariates, or (c) intermittent missing data. To address (a) and (b), one could use the linking model proposed by Rotnitzky et al. 15 coupled with an extension of the inferential ideas discussed here. To handle (c), one could impute intermittent observations, under a reasonable assumption 29 to create a monotone data structure and then apply the methods outlined in this paper with proper accounting for uncertainty in the imputation process.
We believe that the methods and software that we have developed should be applied to all trials with missing outcome data, including but not limited to those that are patient reported. Trial results that are sensitive to untestable assumptions about the missing data mechanism should be viewed with skepticism, while greater credence should be given those that exhibit robustness. Our methods are not a substitute for study designs and procedures that minimize missing data.
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Notes a. We focused on randomized trials in which patients in each treatment group were scheduled to be interviewed at a common set of post baseline assessment times. We excluded crossover trials, 10 trials in which patients were at high risk of death during the scheduled follow-up period, and 6 studies which did not report follow-up rates at the assessment times. b. Data were abstracted from the clinical study report available at http://psychrights.org/research/Digest/NLPs/Seroquel/ UnsealedSeroquelStudies/. The number of patients that were abstracted does not exactly match the number of patients reported in Calabrese et al. 20 c. These sample sizes exclude three randomized patients -one from placebo and two from 600 mg/day Quetiapine. From each group, one patient was removed because of undue influence on the analysis. In the 600 mg/day Quetiapine arm, one patient had incomplete questionnaire data at baseline. d. All confidence intervals are symmetric studentized-t bootstrap with jackknife standard errors. e. According to Dr. Dennis Rivicki and Dr. Jean Endicott, there is no evidence to suggest that there is a differential effect of a unit change in QLESSF on the hazard of drop-out based on its location on the scale.
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